Rayliant NxtGen Multifactor Emerging Markets Equity ETF (RWEM)

BTW. Check out this lovely link i just found about the receiver. Laughable. https://robert-w-berleth.com/

Thank you! I got in today at 12.80 and so glad I did. I'm hoping it gaps and runs tomorrow and does the same on Wed on NYSE! I've never been in an OTC that opened on the NYSE so this is exciting.

Looking good $nvda

CCSC Technology International Holdings Ltd. is a holding company with interests in the design, manufacture, and sale of interconnect products. Its products include cable and wire harness, and connectors. It operates through the following geographical segments: Europe, Asia, Americas, and Others. The

I'm confused. So the receiver is terminated as an interpleader party in the major, big case, but is still going to be the receiver in a NEW case being filed? This doesn't make any sense. Unless there is something going on under the table

USMJ: Volume 792,162

Great day here $tsla congratulations elon musk and shareholders

Cause it’s been a pump and dump that began in the run up in 2024. We’re down trending back to 0.03 and it’s quite easy to see that. Revenue doesn’t matter. Andas dont matter. You’re just liquidity purchasing this stock. Do not buy unless you want to feed the longs profits. It’s over.

Cause it’s been a pump and dump that began in the run up in 2024. We’re down trending back to 0.03 and it’s quite easy to see that. Revenue doesn’t matter. Andas dont matter. You’re just liquidity purchasing this stock. Do not buy unless you want to feed the longs profits. It’s over.

So what didn’t you know - that the OTC is high risk or you don’t always make quick money on a high risk investment.

When they do not make fusion work. Since they have nothing that does. They will just keep on diluting. Eventually when all see they have nothing. Look out below. In the mean time trade it not hold it to see product work.

Note: not “we are supporting” and not “any old trial” but well designed trials.

>>Cancer vaccines
We will support the UK’s ambition to lead
on cancer vaccines by enabling well-
designed trials and proportionate regulation
to accelerate patient access to new

Lots of misinformation this afternoon (not that any of it means a darn thing anyway) but I want to clear up that to the best of my understanding and knowledge INPHI was not related in any corporate way or any other way to Lumera/Gigoptix/Gigpeak/.

Might want to try double checking a

They stayed off their lows
like the plague...good sign
for tomorrow...and give up
red meat, we really fly

What does that mean in revenues. Again never tell us in PR;s. Never file financials. Why. Do not sell much, losses and billions more in dilution. If results were good they file. Wake up it is scam.

Shareholders must ignore ANY attempt at a Company valuation, without credentials and without standing according to the SEC. No bonified expert in 21st century trading uses a manufacturing fundamental methodology which has no basis in technology or B2B business .

There are SEC Fin

And there it goes again … SUNE 💵💵💵

Xeriant (XERI), what a winner!

I guess because they want to preserve an honest reporting reputation.
You know the good and the bad about housing

Figures. Seen it before. News of pink current and then buyers on the news followed by more buyers with FOMO. Then, after a nice pop in the morning, the SELLERS ON NEWS dump some on them and down the pps goes. :-(

Oh well. Glad I didn't buy in the morning like I used to.

CCTG next 2000% 🤣🤣🚬🧨

Can’t be regular.Congratulations to all the happy ones who made a lot Bucks here.But apart from that, it can’t be serious/honest/legal or anything like that.But much fun with spreading the money after selling this

Totally agree that if there are any inroads into the Fibrate market, the Generics will take the majority of it. I say if because the FDA has been knocking fibrates for years and there are still a ton of scripts written for them. State of knowledge or education within the medical community.

Just oversold my opinion. 

Fluidity is also important with dividend-paying companies. Where do you get your information from?